Benazepril HCl 40 mg Tablets, Fasting

NCT ID: NCT00836576

Last Updated: 2024-08-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2001-02-28
• Study Completion Date: 2001-03-31

Brief Summary

The objective of this randomized, single-dose, two-way crossover evaluation is to compare the oral bioavailability of a test benazepril HCl formulation (TEVA Pharmaceutical Industries Ltd.) to an equivalent oral dose of the commercially available benazepril HCl (Lotensin®, Novartis Pharmaceuticals Corporation) in a test population of 40 adults under fasting conditions.

Detailed Description

Criteria for Evaluation: FDA Bioequivalence Criteria

Statistical Methods: FDA bioequivalence statistical methods

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

1

Group Type: EXPERIMENTAL

Benazepril HCl 40 mg Tablets

Intervention Type: DRUG

1 x 40 mg, single-dose fasting

2

Group Type: ACTIVE_COMPARATOR

Lotensin® 40 mg Tablets

Intervention Type: DRUG

1 x 40 mg, single-dose fasting

Interventions

Benazepril HCl 40 mg Tablets

1 x 40 mg, single-dose fasting

Intervention Type: DRUG

Lotensin® 40 mg Tablets

1 x 40 mg, single-dose fasting

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Sex: Male and Female; similar proportions of each preferred.
• Age: At least 18 years.
• Subjects must have a minimum weight of at least 110 pounds.
• Qualifying subjects must be in good health and physical condition as determined by medical history, complete physical examination, and laboratory tests, all obtained within four (4) weeks prior to study start. The subject may not have a history of significant past illness expected to affect the investigation. The normal status of subjects will be confirmed by the following procedures:

1. Laboratory Tests: Hemoglobin, hematocrit, RBC, WBC, differential count, serum electrolytes (Na, K, Cl), fasting blood glucose, BUN, bilirubin, creatinine, AST, ALT, LDH, alkaline phosphatase, and urinalysis. HIV, Hepatitis B, Hepatitis C, and drugs of abuse testing will be done for screening purposes only. Laboratory values which are greater than ± 20% of the normal range will not qualify unless specifically accepted (with comment) by the Principal Investigator. Results of HIC, Hepatitis B, Hepatitis C, and drugs of abuse must be negative or non-reactive for the subject to qualify for the study. Additional drugs of abuse testing will be done at check-in for each period. Tests are to be negative as a requirement for dosing. Female subjects will have a urine pregnancy test done at screening and prior to each study period at check-in.

2. Electrocardiogram: A 12-lead electrocardiogram will be obtained for all subjects. The original tracings, plus interpretation, will be included in the case report form packet.

• Subjects must read and sign the Consent Form.

• In addition one of the conditions listed below will exclude a subject from the study:

1. History of treatment for alcoholism, drug abuse, or substance abuse within the past 24 months.

2. History of malignancy, stroke, diabetes, cardiac, renal or liver disease, or other serious illness.

3. History of treatment for asthma within the past five (5) years.

4. History of treatment for any gastrointestinal disorder within the past five (5) years.

5. History of neutropenia.

6. History of hyperkalemia.

7. History of angioedema.

8. History of impaired renal function.

9. History of persistent nonproductive cough.

10. Females who are pregnant or lactating.

11. History of hypersensitivity to benazepril HCl, or any angiotensin-converting enzyme (ACE) inhibitor.

• Conditions upon screening which might contraindicate or require that caution be used in the administration of benazepril HCl, including:

1. Sitting systolic blood pressure below 90 mmHg, or diastolic pressure below 50 mmHg.

2. Heart rate less than 50 beats per minute after a 5-minute rest in a seated position.

• Inability to read and/or sign the consent form.
• Treatment with any other investigational drug during the four (4) weeks prior to enrollment into the study.
• Subjects who have donated blood within four (4) weeks prior to entry into the study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Teva Pharmaceuticals USA

INDUSTRY

Sponsor Role: lead

Principal Investigators

Thomas Siler, M.D.

Role: PRINCIPAL_INVESTIGATOR

Cetero Research, San Antonio

Locations

Gateway Medical Research, Inc.

Saint Charles, Missouri, United States

Countries

United States

Other Identifiers

01002

Identifier Type: -

Identifier Source: org_study_id